Singulair and Nateglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Singulair (montelukast sodium) and Nateglinide (nateglinide). Common drug interactions include dyspnoea among females and anaphylactic reaction among males.

The phase IV clinical study analyzes what interactions people have when they take Singulair and Nateglinide. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.

What is Nateglinide?

Nateglinide has active ingredients of nateglinide. It is often used in type 2 diabetes. eHealthMe is studying from 1,771 Nateglinide users. Check the latest studies of Nateglinide.



On Jul, 12, 2026

17 people who take Singulair and Nateglinide together, and have interactions are studied.

Singulair and Nateglinide drug interactions.

What are the common drug interactions of Singulair and Nateglinide, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Pancreatic disorder
  3. Sinusitis (inflammation of sinus)
  4. Abdominal pain upper
  5. Alopecia (absence of hair from areas of the body)
  6. Aphonia (inability to produce voice)
  7. Arthropathy
  8. Blindness unilateral
  9. Blood glucose decreased
  10. Cardiac failure congestive

male:

  1. Anaphylactic reaction (serious allergic reaction)
  2. Anger
  3. Dandruff
  4. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  5. Prostate cancer
  6. Psoriasis (immune-mediated disease that affects the skin)
  7. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  8. Tooth extraction
  9. Cd4 lymphocytes decreased
  10. Cd8 lymphocytes decreased

What are the common drug interactions of Singulair and Nateglinide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Dizziness
  2. Listless (lack of interest, energy, or spirit)
  3. Somnolence (a state of near-sleep, a strong desire for sleep)
  4. Unresponsive to stimuli

60+:

  1. Anaphylactic reaction (serious allergic reaction)
  2. Anger
  3. Aphonia (inability to produce voice)
  4. Arthropathy
  5. Blindness unilateral
  6. Cardiac failure congestive
  7. Cataract (clouding of the lens inside the eye)
  8. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  9. Dry mouth
  10. Dyspnoea exertional (breathlessness or shortness of breath)

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 29.41%
  2. Urticaria (rash of round, red welts on the skin that itch intensely): 3 people, 17.65%
  3. Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 3 people, 17.65%
  4. Enlarged Prostate: 3 people, 17.65%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 17.65%
  6. Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 17.65%
  7. Hypersensitivity: 3 people, 17.65%
  8. Intention Tremor (brain tremor): 3 people, 17.65%
  9. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 17.65%
  10. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 17.65%

* Approximation only. Some reports may have incomplete information.

Do you take Singulair and Nateglinide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Singulair and Nateglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nateglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Singulair and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nateglinide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on montelukast sodium and nateglinide (the active ingredients of Singulair and Nateglinide, respectively), and Singulair and Nateglinide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: